+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Ophthalmic Drugs market valued at $23bn in 2017” says Visiongain report

19 July 2017
Pharma

Visiongain’ has launched a new pharma report Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018 – 2028 : Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas. Key patent expirations have affected revenues in this market in recent years, particularly in the glaucoma segment.

The lead analyst of the report commented “Considerable success in the ophthalmic pharmaceutical market is likely for therapies that will accommodate the large unmet need for pharmacological therapies for currently-untreated ophthalmic conditions. Certain conditions, where surgery is the only treatment, have an unmet patient need for pharmaceutical treatments.

However, to be commercially successful, new products must overcome significant hurdles. These include the challenge of demonstrating efficacy and safety during regulatory approval (especially for chronic diseases), achieving adequate reimbursement, and addressing the growing threat of generic competition.”

Leading companies featured in the report include Akorn, Alcon, Allergan, Bausch & Lomb, Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

Read

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

Read

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

Read